Search results
Results from the WOW.Com Content Network
You can often tell the health of the stock market by the number and performance of initial public offerings, or IPOs. As 2022 has seen a bear market in the major averages, it's not surprising at ...
This page was last edited on 3 February 2024, at 22:53 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
This was the largest Canadian biotech IPO in more than a decade. [5] By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across ...
Follow @leokornsun In 2013, 33 biotech companies went public, raising a total of $2.5 billion from their IPOs and easily eclipsing the previous record of 26 biotech companies that raised $1.9 ...
For premium support please call: 800-290-4726 more ways to reach us
In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol ...